Pliant Therapeutics downgraded by Leerink Partners
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Leerink Partners downgraded Pliant Therapeutics from Outperform to Market Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | Buy → Hold | Needham | |
| 3/4/2025 | Neutral | Cantor Fitzgerald | |
| 3/3/2025 | Buy → Hold | Stifel | |
| 3/3/2025 | Outperform → Market Perform | Leerink Partners | |
| 2/10/2025 | Overweight → Neutral | Analyst | |
| 2/10/2025 | $43.00 → $4.00 | Buy → Hold | Canaccord Genuity |
| 2/10/2025 | Outperform → Perform | Oppenheimer | |
| 2/10/2025 | $40.00 → $4.00 | Buy → Neutral | Citigroup |
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results demonstrated PLN-101095 anti-tumor activity in combination with
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r
Needham downgraded Pliant Therapeutics from Buy to Hold
Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral
Stifel downgraded Pliant Therapeutics from Buy to Hold
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced
Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-A12B - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
SCHEDULE 13D - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)